- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04346719
Percutaneous High Frequency Alternating Current Stimulation in Healthy Volunteers
Percutaneous High Frequency Alternating Current Stimulation: Effects on Somatosensory and Motor Threshold in Healthy Volunteers
Study Overview
Status
Conditions
Detailed Description
Our previous studies with transcutaneous HFAC, suggest high-frequency stimulation (10 and 20 kHz) have an inhibitory effect over muscle strength and somatosensory threshold.
However, in these studies the intensity needed to reach block threshold is very high. The purpose of the present work is to reduce the amount of current intensity needed using a percutaneous approach by apply two acupuncture needles near the nerve as electrodes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toledo, Spain, 45071
- Castilla-La Mancha University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers
- Ability to perform all clinical tests and understand the study process, as well as obtaining informed consent.
- Tolerance to the application of electrotherapy.
- That they have not diagnosed any pathology.
- They do not present a contraindication to puncture and / or the application of electric currents.
Exclusion Criteria:
- Neuromuscular disease.
- Epilepsy.
- Trauma, surgery or pain affecting the upper limb
- Osteosynthesis material in the upper limb.
- Diabetes.
- Cancer.
- Cardiovascular disease.
- Pacemaker or other implanted electrical device.
- Take any drug (NSAIDs, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days.
- Presence of tattoos or other external agent introduced into the treatment or assessment area.
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 10 kHz stimulation
Transcutaneous application of high frequency electrical current at 10 kHz over the median nerve for a 20 minutes session.
The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.
|
A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 10 kHz.
The stimulation intensity will be defined as that sufficient to produce a "strong but comfortable" sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932.
(Enraf-Nonius, Delft,Netherlands)
|
|
Experimental: 20 kHz stimulation
Transcutaneous application of high frequency electrical current at 20 kHz over the median nerve for a 20 minutes session.
The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.
|
A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 20 kHz.
The stimulation intensity will be defined as that sufficient to produce a "strong but comfortable" sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932.
(Enraf-Nonius, Delft,Netherlands)
|
|
Sham Comparator: Sham stimulation
Electrodes are placed over the median nerve for 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity during the first 30 seconds.
|
Sham stimulation will be delivered at a frequency of 10 kHz only during the first 30 seconds.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Antidromic median sensory nerve action potential
Time Frame: Baseline at 0 minutes
|
The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint).
The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd).
Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).
|
Baseline at 0 minutes
|
|
Tactile Threshold
Time Frame: Baseline at 0 minutes
|
The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
|
Baseline at 0 minutes
|
|
Oscillation Frequency of tissue assessed by MyotonPro
Time Frame: Baseline at 0 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The frequency of the damped oscillations characterizes the muscle tone.
The muscle will be assessed is opponens pollicis muscle
|
Baseline at 0 minutes
|
|
Stiffness of tissue assessed by MyotonPro
Time Frame: Baseline at 0 minutes
|
This outcome measure is obtained by a device named MyotonPro.
Stiffness reflects the resistance of the muscle to the force deforming the muscle.
The muscle will be assessed is opponens pollicis muscle
|
Baseline at 0 minutes
|
|
Decrement (elasticity) of tissue assessed by MyotonPro
Time Frame: Baseline at 0 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction.
The muscle will be assessed is opponens pollicis muscle
|
Baseline at 0 minutes
|
|
Pressure Pain Threshold
Time Frame: Baseline at 0 minutes
|
The PPT will be measured with an algometer and will be expressed in Newtons
|
Baseline at 0 minutes
|
|
Muscle strength
Time Frame: Baseline at 0 minutes
|
Muscle strength will be measured with a dynamometer and will be expressed in Kgs.
|
Baseline at 0 minutes
|
|
Tactile Threshold
Time Frame: During treatment at 15 minutes
|
The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
|
During treatment at 15 minutes
|
|
Oscillation Frequency of tissue assessed by MyotonPro
Time Frame: During treatment at 15 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The frequency of the damped oscillations characterizes the muscle tone.
The muscle will be assessed is opponens pollicis muscle
|
During treatment at 15 minutes
|
|
Stiffness of tissue assessed by MyotonPro
Time Frame: During treatment at 15 minutes
|
This outcome measure is obtained by a device named MyotonPro.
Stiffness reflects the resistance of the muscle to the force deforming the muscle.
The muscle will be assessed is opponens pollicis muscle
|
During treatment at 15 minutes
|
|
Decrement (elasticity) of tissue assessed by MyotonPro
Time Frame: During treatment at 15 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction.
The muscle will be assessed is opponens pollicis muscle
|
During treatment at 15 minutes
|
|
Pressure Pain Threshold
Time Frame: During treatment at 15 minutes
|
The PPT will be measured with an algometer and will be expressed in Newtons
|
During treatment at 15 minutes
|
|
Antidromic median sensory nerve action potential
Time Frame: Immediately after treatment at 20 minutes
|
The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint).
The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd).
Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).
|
Immediately after treatment at 20 minutes
|
|
Tactile Threshold
Time Frame: Immediately after treatment at 20 minutes
|
The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
|
Immediately after treatment at 20 minutes
|
|
Oscillation Frequency of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 20 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The frequency of the damped oscillations characterizes the muscle tone.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 20 minutes
|
|
Stiffness of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 20 minutes
|
This outcome measure is obtained by a device named MyotonPro.
Stiffness reflects the resistance of the muscle to the force deforming the muscle.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 20 minutes
|
|
Decrement (elasticity) of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 20 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 20 minutes
|
|
Pressure Pain Threshold
Time Frame: Immediately after treatment at 20 minutes
|
The PPT will be measured with an algometer and will be expressed in Newtons
|
Immediately after treatment at 20 minutes
|
|
Muscle strength
Time Frame: Immediately after treatment at 20 minutes
|
Muscle strength will be measured with a dynamometer and will be expressed in Kgs.
|
Immediately after treatment at 20 minutes
|
|
Antidromic median sensory nerve action potential
Time Frame: Immediately after treatment at 30 minutes
|
The recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint).
The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd).
Negative peak latency (NPL), positive peak latency (PPL), and peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED).
|
Immediately after treatment at 30 minutes
|
|
Tactile Threshold
Time Frame: Immediately after treatment at 30 minutes
|
The tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
|
Immediately after treatment at 30 minutes
|
|
Oscillation Frequency of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 30 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The frequency of the damped oscillations characterizes the muscle tone.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 30 minutes
|
|
Stiffness of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 30 minutes
|
This outcome measure is obtained by a device named MyotonPro.
Stiffness reflects the resistance of the muscle to the force deforming the muscle.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 30 minutes
|
|
Decrement (elasticity) of tissue assessed by MyotonPro
Time Frame: Immediately after treatment at 30 minutes
|
This outcome measure is obtained by a device named MyotonPro.
The logarithmic decrement of the damping oscillations characterizes muscle elasticity which is the ability of the muscle to restore its initial shape after contraction.
The muscle will be assessed is opponens pollicis muscle
|
Immediately after treatment at 30 minutes
|
|
Pressure Pain Threshold
Time Frame: Immediately after treatment at 30 minutes
|
The PPT will be measured with an algometer and will be expressed in Newtons
|
Immediately after treatment at 30 minutes
|
|
Muscle strength
Time Frame: Immediately after treatment at 30 minutes
|
Muscle strength will be measured with a dynamometer and will be expressed in Kgs.
|
Immediately after treatment at 30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline nerve temperature
Time Frame: Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes
|
Nerve temperature will be measured using a termodoppler (Celsius degrees)
|
Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes
|
|
Baseline flux temperature
Time Frame: Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes
|
Flux will be measured using a termodoppler
|
Baseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutes
|
|
Numerical Discomfort Rate Score
Time Frame: After the intervention at 35 minutes
|
the possible discomfort caused by the interventions will be assess by a numerical rate score.
The NRS consists of a scale from 0 (no discomfort) to 10 (worst possible discomfort)
|
After the intervention at 35 minutes
|
|
Numerical Pain Rate Score
Time Frame: After the intervention at 35 minutes
|
The NRS consists of a scale from 0 (no pain) to 10 (worst possible pain)
|
After the intervention at 35 minutes
|
|
Number of participants with intervention-related adverse effects
Time Frame: After the intervention at 35 minutes
|
the possible adverse effects caused by the interventions will be assess by a questionnaire
|
After the intervention at 35 minutes
|
|
Blinding success
Time Frame: After the intervention at 35 minutes
|
Blinding of subjects and researchers will be assessed using the James Index
|
After the intervention at 35 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Juan Avendaño-Coy, PhD, Castilla-La Mancha University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- Neuromodest-pHFAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Electrical Stimulation
-
University of BrasiliaUniversity of BurgundyCompletedElectrical StimulationBrazil
-
University of BrasiliaUniversity of BurgundySuspendedElectrical StimulationBrazil
-
Biruni UniversityRecruitingNeuromuscular Electrical StimulationTurkey (Türkiye)
-
University of Castilla-La ManchaCompletedElectrical Stimulation | NeuromodulationSpain
-
National Cheng-Kung University HospitalCompletedTranscranial Electrical Stimulation
-
University of Castilla-La ManchaCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Nanfang Hospital, Southern Medical UniversityRecruitingTranscutaneous Electrical Acupoint StimulationChina
-
Washington University School of MedicineCompletedTranscranial Electrical Stimulation (tES)United States
-
Seoul National University HospitalNational Research Foundation of KoreaCompletedElectrical Stimulation | Phrenic NerveKorea, Republic of
Clinical Trials on 10 kHz stimulation (Myomed 932, Enraf-Nonius)
-
University of Castilla-La ManchaCompletedElectrical Stimulation | NeuromodulationSpain
-
Maastricht University Medical CenterCompletedSarcopeniaNetherlands
-
Chang Gung UniversityUnknown
-
Universidad Complutense de MadridCompletedOrthognathic Surgery | Physiology | Transcutaneous Electric Nerve StimulationSpain
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Shiraz University of Medical SciencesCompletedInterferential Current Drug DeliveryIran, Islamic Republic of